Gore ASSURED Clinical Study results through 36 months demonstrate 100 percent closure success * with the GORE ® CARDIOFORM ASD Occluder, and consistent safety outcomes † across a broad range of ASD ...

FLAGSTAFF, Ariz.- W. L. Gore & Associates (Gore) announced the U.S. Food and Drug Administration's (FDA's) premarket approval (PMA) of the GORE® CARDIOFORM ASD Occluder for the percutaneous closure of ...

A retrospective comparison of six patent foramen ovale (PFO) closure devices used in the United States over 18 years shows a trade-off between effectiveness and arrhythmia. Specifically, the ...

FLAGSTAFF, Ariz., March 11, 2021 /CNW/ -- W. L. Gore & Associates (Gore), today announced that Gore REDUCE Study long-term follow-up results were published in the March 2021 issue of The New England ...

After a decade of clinical use* and more than 50,000 devices sold globally, the GORE® CARDIOFORM Septal Occluder continues a trusted legacy of safely advancing care. FLAGSTAFF, Ariz., Jan. 20, 2022 ...

W.L. Gore is bringing its Cardioform ASD Occluder to Europe. The Flagstaff, AZ-based company announced Wednesday it received CE mark for the device, which can close atrial defects (ASDs). The device ...

FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) announces positive results from its REDUCE Study assessing closure of patent foramen ovale (PFO) for the reduction of recurrent ...

The FDA has given its final nod to W.L. Gore & Associates Inc. to market the Cardioform ASD occluder, aimed at correcting a congenital anomaly that causes a hole in the wall between the two upper ...

Gore REDUCE Clinical Study Five-Year Results Demonstrate That PFO Closure With The GORE® CARDIOFORM Septal Occluder Provides Safe Long-Term Reduction Of Recurrent Stroke - Published in the New England ...

After a decade of clinical use* and more than 50,000 devices sold globally, the GORE® CARDIOFORM Septal Occluder continues a trusted legacy of safely advancing care. Now, after 10 years of clinical ...